Skip to content

Released Mar 7, 2024, before the open

10-K filed Mar 7, 2024, 67 days after period end · 0001785530-24-000012

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$12.00MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$12,962,000N/M
Operating Cash Flowderived-$4,585,000N/M
Free Cash Flowderived-$4,783,000N/M

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Net Income-$12.00M-$11.93M-$17.87M-$7.40M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR